Privia Health Group (PRVA) Stock Forecast & Price Target

Compare

196 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PRVA Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Privia

Health Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PRVA Stock 12 Month Forecast

Average Price Target

$29.00

▲(31.82%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Privia Health Group in the last 3 months. The average price target is $29.00 with a high forecast of $32.00 and a low forecast of $24.00. The average price target represents a 31.82% change from the last price of $22.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","33":"$33","20.25":"$20.3","24.5":"$24.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,20.25,24.5,28.75,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.83,23.535384615384615,24.240769230769228,24.946153846153845,25.65153846153846,26.356923076923074,27.06230769230769,27.767692307692307,28.473076923076924,29.178461538461537,29.883846153846154,30.589230769230767,31.294615384615383,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.83,23.30461538461538,23.779230769230768,24.25384615384615,24.728461538461538,25.20307692307692,25.677692307692308,26.15230769230769,26.626923076923077,27.10153846153846,27.576153846153847,28.05076923076923,28.525384615384617,{"y":29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.83,22.919999999999998,23.009999999999998,23.099999999999998,23.189999999999998,23.279999999999998,23.369999999999997,23.46,23.55,23.64,23.73,23.82,23.91,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.03,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$32.00

Average Price Target$29.00

Lowest Price Target$24.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$26

Buy

18.18%

Upside

Reiterated

06/11/25

Privia Health Group's overall stock score is driven by its strong financial performance and positive earnings call outcomes. While technical analysis and valuation present challenges, the company's strategic growth and solid corporate governance contribute to a favorable outlook. However, high valuation metrics and sector-specific challenges warrant cautious optimism.

Ryan LangstonTD Cowen

TD Cowen

$30

Buy

36.36%

Upside

Reiterated

06/16/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Sarepta Therapeutics (NASDAQ: SRPT) and Privia Health Group (NASDAQ: PRVA)

Lisa GillJ.P. Morgan

J.P. Morgan

$29→$32

Buy

45.45%

Upside

Reiterated

05/28/25

Privia Health price target raised to $32 from $29 at JPMorganPrivia Health price target raised to $32 from $29 at JPMorgan

Andrew Mok CFABarclays

Barclays

$23→$24

Hold

9.09%

Upside

Reiterated

05/27/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Envista Holdings (NYSE: NVST) and Privia Health Group (NASDAQ: PRVA)

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$27→$30

Buy

36.36%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Voyager Therapeutics (NASDAQ: VYGR) and Privia Health Group (NASDAQ: PRVA)

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/09/25

Privia Health Group (PRVA) Receives a Buy from Truist Financial

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

Privia Health Group: Strong Financial Performance and Strategic Growth Positioning Justify Buy Rating

Whit MayoLeerink Partners

Leerink Partners

$30→$32

Buy

45.45%

Upside

Reiterated

05/08/25

Privia Health Group's Strong Performance and Strategic Expansion Drive Positive Outlook

Constantine DavidesCitizens JMP

Citizens JMP

$29

Buy

31.82%

Upside

Reiterated

04/28/25

Citizens JMP reiterates Market Outperform Rating on Privia Health Group Inc (PRVA)Citizens JMP analyst Constantine Davides reiterated a Market Outperform rating and $29.00 price target on Privia Health Group Inc (NASDAQ: PRVA).

Michael HaRobert W. Baird

Robert W. Baird

$24→$26

Buy

18.18%

Upside

Reiterated

04/15/25

Privia Health price target raised to $26 from $24 at BairdPrivia Health price target raised to $26 from $24 at Baird

Matthew SheaNeedham

Needham

$25→$30

Buy

36.36%

Upside

Reiterated

03/21/25

Needham Reaffirms Their Buy Rating on Privia Health Group (PRVA)

Jeffrey GarroStephens

Stephens

$26→$30

Buy

36.36%

Upside

Reiterated

03/05/25

Privia Health Group Inc (PRVA) PT Raised to $30 at StephensStephens analyst Jeff Garro raised the price target on Privia Health Group Inc (NASDAQ: PRVA) to $30.00 (from $26.00) while maintaining a Overweight rating.

David LarsenBTIG

BTIG

$35

Buy

59.09%

Upside

Reiterated

03/05/25

BTIG Keeps Their Buy Rating on Privia Health Group (PRVA)

Jack SlevinJefferies

Jefferies

$27→$29

Buy

31.82%

Upside

Reiterated

03/04/25

Privia Health Group Inc (PRVA) PT Raised to $29 at JefferiesJefferies analyst Jack Slevin raised the price target on Privia Health Group Inc (NASDAQ: PRVA) to $29.00 (from $27.00) while maintaining a Buy rating.

Michael Craig JonesStifel Nicolaus

Stifel Nicolaus

$26→$30

Buy

36.36%

Upside

Reiterated

03/03/25

Privia Health Group (PRVA) Gets a Buy from Stifel Nicolaus

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$26

Buy

18.18%

Upside

Reiterated

06/11/25

Ryan LangstonTD Cowen

TD Cowen

$30

Buy

36.36%

Upside

Reiterated

06/16/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Sarepta Therapeutics (NASDAQ: SRPT) and Privia Health Group (NASDAQ: PRVA)

Lisa GillJ.P. Morgan

J.P. Morgan

$29→$32

Buy

45.45%

Upside

Reiterated

05/28/25

Privia Health price target raised to $32 from $29 at JPMorganPrivia Health price target raised to $32 from $29 at JPMorgan

Andrew Mok CFABarclays

Barclays

$23→$24

Hold

9.09%

Upside

Reiterated

05/27/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Envista Holdings (NYSE: NVST) and Privia Health Group (NASDAQ: PRVA)

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$27→$30

Buy

36.36%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Voyager Therapeutics (NASDAQ: VYGR) and Privia Health Group (NASDAQ: PRVA)

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/09/25

Privia Health Group (PRVA) Receives a Buy from Truist Financial

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

Privia Health Group: Strong Financial Performance and Strategic Growth Positioning Justify Buy Rating

Whit MayoLeerink Partners

Leerink Partners

$30→$32

Buy

45.45%

Upside

Reiterated

05/08/25

Privia Health Group's Strong Performance and Strategic Expansion Drive Positive Outlook

Constantine DavidesCitizens JMP

Citizens JMP

$29

Buy

31.82%

Upside

Reiterated

04/28/25

Michael HaRobert W. Baird

Robert W. Baird

$24→$26

Buy

18.18%

Upside

Reiterated

04/15/25

Privia Health price target raised to $26 from $24 at BairdPrivia Health price target raised to $26 from $24 at Baird

Matthew SheaNeedham

Needham

$25→$30

Buy

36.36%

Upside

Reiterated

03/21/25

Needham Reaffirms Their Buy Rating on Privia Health Group (PRVA)

Jeffrey GarroStephens

Stephens

$26→$30

Buy

36.36%

Upside

Reiterated

03/05/25

David LarsenBTIG

BTIG

$35

Buy

59.09%

Upside

Reiterated

03/05/25

BTIG Keeps Their Buy Rating on Privia Health Group (PRVA)

Jack SlevinJefferies

Jefferies

$27→$29

Buy

31.82%

Upside

Reiterated

03/04/25

Michael Craig JonesStifel Nicolaus

Stifel Nicolaus

$26→$30

Buy

36.36%

Upside

Reiterated

03/03/25

Privia Health Group (PRVA) Gets a Buy from Stifel Nicolaus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Privia Health Group

1 Month

xxx

Success Rate

8/22 ratings generated profit

Average Return

-0.87%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 36.36% of your transactions generating a profit, with an average return of -0.87% per trade.

3 Months

xxx

Success Rate

10/22 ratings generated profit

Average Return

+0.22%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +0.22% per trade.

1 Year

Constantine DavidesCitizens JMP

Success Rate

5/8 ratings generated profit

Average Return

+8.03%

reiterated a buy rating 2 months ago

Copying Constantine Davides's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +8.03% per trade.

2 Years

xxx

Success Rate

5/8 ratings generated profit

Average Return

+3.95%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +3.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRVA Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PRVA has received 12 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. PRVA average Analyst price target in the past 3 months is 29.00.

Each month's total comprises the sum of three months' worth of ratings.

PRVA Financial Forecast

PRVA Earnings Forecast

Next quarter’s earnings estimate for PRVA is $0.05 with a range of $0.02 to $0.08. The previous quarter’s EPS was $0.03. PRVA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year PRVA has Preformed in-line its overall industry.

PRVA Sales Forecast

Next quarter’s sales forecast for PRVA is $467.03M with a range of $455.40M to $494.32M. The previous quarter’s sales results were $480.10M. PRVA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year PRVA has Outperformed its overall industry.

PRVA Stock Forecast FAQ

What is PRVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Privia Health Group’s 12-month average price target is 29.00.

What is PRVA’s upside potential, based on the analysts’ average price target?

Privia Health Group has 31.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PRVA a Buy, Sell or Hold?

Privia Health Group has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Privia Health Group’s price target?

The average price target for Privia Health Group is 29.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $24.00. The average price target represents 31.82% Increase from the current price of $22.

What do analysts say about Privia Health Group?

Privia Health Group’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of PRVA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Privia Health Group (PRVA) Stock Forecast & Price Target

PRVA Analyst Ratings

PRVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Privia Health Group

PRVA Analyst Recommendation Trends

PRVA Financial Forecast

PRVA Earnings Forecast

PRVA Sales Forecast

PRVA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts